Ingevity Corporation
NYSE:NGVTChemicals - Specialty
+$0.81 today
- Market cap
- $1.97B
- Beta
- 1.19
- P/E (TTM)
- -20.0
- EPS (TTM)
- -$3.62
Volume 0.37M
Average 0.26M
NGVT Revenue
Total income from selling goods and services before any costs are deducted; the top line of the income statement.
Ingevity CorporationNYSE: NGVT
Revenue · Q3 FY2026 · quarter ended Sep 2026
Revenue declines year over year
Q3 FY2026 revenue of $305.1M fell 8.4% year over year, ahead of the -11.6% change in trailing-twelve-month revenue. Sequentially, it fell 2.9% from the prior quarter. Over 3 fiscal years it compounded at -11.2% a year.
Context
- Revenue increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether revenue reaches the consensus estimate from 2 analysts of $1.11B (-5.2%) for the fiscal year ending Dec 2026, a step up from the -17.0% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- $305.1M-2.9% QoQ
- Last fiscal yearDec 2025
- $1.17B-17.0% YoY
- LTMSep 2026
- $1.13B-11.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -8.4% | -9.1% | -0.7 pp |
| 1 year | -17.0% | -5.2% | +11.7 pp |
| 3-year CAGR | -11.2% | -0.2% | +11.0 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Revenue history
USD · from the income statement
- Latest · FY2025
- 1.17B USD
- Year-over-year change
- -17.0%
- 4-year CAGR
- -4.3%
| Period | Period end | Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.17B | -17.0% |
| FY2024 | 2024-12-31 | 1.41B | -16.9% |
| FY2023 | 2023-12-31 | 1.69B | +1.4% |
| FY2022 | 2022-12-31 | 1.67B | +19.9% |
| FY2021 | 2021-12-31 | 1.39B | — |
Revenue vs competitors
How NGVT compares with its peers on the latest reported figures
- Peers report in different currencies, so revenue is compared through growth and rates rather than absolute size.
- Its year-over-year change of -11.6% is the 9th highest of 10, against a peer median of +0.6%.
- Over three fiscal years its annual growth of -11.2% compares with a peer median of -4.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | $6.7B USD | +0.6% | -10.2% | |
| LTM Jun 2026 | $5.8B USD | -1.4% | -5.3% | |
| LTM Mar 2026 | $3.43B USD | -16.6% | -15.8% | |
| LTM Apr 2026 | $2.13B USD | +2.5% | -0.8% | |
| LTM Sep 2026 | $2.03B USD | +8.7% | -1.0% | |
| LTM Jun 2026 | $1.84B USD | -1.4% | -8.6% | |
| LTM Jun 2026 | $1.84B USD | +2.9% | -3.3% | |
AAUCAllied Gold Corporation | LTM Jun 2026 | $1.49B USD | +55.3% | +25.8% |
| LTM Sep 2026 | $1.13B USD | -11.6% | -11.2% | |
ELVRElevra Lithium Limited | FY2025 | A$207.24M AUD | -7.2% | — |
| LTM Sep 2026 | CA$0 CAD | — | — | |
| Peer median (excluding NGVT) | — | +0.6% | -4.3% | |
Competitors are the stored peer set for NGVT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.39B | 1.67B | 1.69B | 1.41B | 1.17B |
| Cost of Revenue | 878.7M | 1.1B | 1.22B | 951.7M | 706.1M |
| Gross Profit | 512.8M | 570.1M | 471.9M | 454.7M | 461.5M |
| Gross Margin | 36.9% | 34.2% | 27.9% | 32.3% | 39.5% |
| Research & Development | 26.3M | 30.3M | 31.8M | 28.1M | 28.4M |
| Selling, General & Admin | 179.3M | 198.8M | 183.7M | 166.7M | 171.2M |
| Operating Expenses | 205.6M | 229.1M | 215.5M | 194.8M | 199.6M |
| Depreciation & Amortization | 109.9M | 108.8M | 122.8M | 108.3M | 106.4M |
| EBITDA | 324.4M | 440.2M | 206M | (329.5M) | 37.4M |
| EBITDA Margin | 23.3% | 26.4% | 12.2% | -23.4% | 3.2% |
| Operating Income | 307.2M | 341M | 256.4M | 259.9M | 261.9M |
| Operating Margin | 22.1% | 20.4% | 15.2% | 18.5% | 22.4% |
| Interest Income | 4M | 5.8M | 6.3M | 6.9M | 4.4M |
| Interest Expense | 51.7M | 61.8M | 93.3M | 97.8M | 77.1M |
| Other Income / Expenses | (144.4M) | (71.4M) | (266.5M) | (795.5M) | (404M) |
| Income Before Tax | 162.8M | 269.6M | (10.1M) | (535.6M) | (142.1M) |
| Pre-Tax Margin | 11.7% | 16.2% | -0.6% | -38.1% | -12.2% |
| Income Tax Expense | 44.7M | 58M | (4.7M) | (105.3M) | 8.2M |
| Net Income | 118.1M | 211.6M | (5.4M) | (430.3M) | (167.1M) |
| Net Margin | 8.5% | 12.7% | -0.3% | -30.6% | -14.3% |
| EPS (Basic) | 2.97 | 5.50 | (0.15) | (11.85) | (4.61) |
| EPS (Diluted) | 2.95 | 5.50 | (0.15) | (11.85) | (4.61) |
| Weighted Avg Shares | 39.8M | 38.47M | 36.5M | 36.32M | 36.2M |
| Weighted Avg Shares (Diluted) | 40.06M | 38.47M | 36.5M | 36.32M | 36.2M |
Ingevity Corporation
NYSE:NGVT
Intrinsic Alpha fair value
Locked
Current Price
$58.31
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.